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Abstract: Since the beginning of the severe SARS-CoV-2 pandemic, an increasing number of countries
reported cases of a systemic hyperinflammatory condition defined as multi-system inflammatory syndrome
in children (MIS-C). The clinical features of MIS-C can be an overlap of Kawasaki Disease (KD), Toxic
Shock Syndrome (TSS), Macrophage Activation Syndrome (MAS), or have often an acute abdominal
presentation. Intravenous immunoglobulin (IVIG) is recommended as first line therapy in KD. Recent
evidence suggests intravenous immunoglobulins (IVIG) resistance in some cases of SARS-CoV-2 related
MIS-C, thereby questioning the benefit of immunomodulators such as IL-1 or IL-6 blocking agents. We
report on a cohort of 6 Swiss children with SARS-CoV2 related MIS-C presenting with clinical features
compatible with Incomplete KD and Toxic Shock Syndrome associated to a cytokine storm. Serum
cytokine profile investigations showed increased IL1RA levels (8 to 22-fold) in 5 of the 6 patients (one
patient had not been tested), whereas, IL-6 serum levels were increased only in the 3 patients of the 6
who were tested. With exception of one patient who had only benefited by Anakinra, all patients received
at least one dose of IVIG. One patient has only received Anakinra with favorable evolution, and three
patients had also a steroid treatment. In addition to all this anti-inflammatory medication two patients
have also received one dose of anti-IL6. In conclusion, our case series reports on clinical and laboratory
findings of most of Swiss cases with MIS-C and suggests the use of Anakinra as an alternative to steroids
in these children, most of whom presented with high IL-1RA levels.
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Since the beginning of the severe SARS-CoV-2 pandemic, an increasing number
of countries reported cases of a systemic hyperinflammatory condition defined as
multi-system inflammatory syndrome in children (MIS-C). The clinical features of MIS-C
can be an overlap of Kawasaki Disease (KD), Toxic Shock Syndrome (TSS), Macrophage
Activation Syndrome (MAS), or have often an acute abdominal presentation. Intravenous
immunoglobulin (IVIG) is recommended as first line therapy in KD. Recent evidence
suggests intravenous immunoglobulins (IVIG) resistance in some cases of SARS-CoV-2
related MIS-C, thereby questioning the benefit of immunomodulators such as IL-1 or
IL-6 blocking agents. We report on a cohort of 6 Swiss children with SARS-CoV2 related
MIS-C presenting with clinical features compatible with Incomplete KD and Toxic Shock
Syndrome associated to a cytokine storm. Serum cytokine profile investigations showed
increased IL1RA levels (8 to 22-fold) in 5 of the 6 patients (one patient had not been
tested), whereas, IL-6 serum levels were increased only in the 3 patients of the 6 who
were tested. With exception of one patient who had only benefited by Anakinra, all
patients received at least one dose of IVIG. One patient has only received Anakinra with
favorable evolution, and three patients had also a steroid treatment. In addition to all this
anti-inflammatory medication two patients have also received one dose of anti-IL6. In
conclusion, our case series reports on clinical and laboratory findings of most of Swiss
cases with MIS-C and suggests the use of Anakinra as an alternative to steroids in these
children, most of whom presented with high IL-1RA levels.
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INTRODUCTION
Since the beginning of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) pandemic, an increasing number
of countries reported cases of a systemic hyperinflammatory
condition defined as multi-system inflammatory syndrome
in children (MIS-C). This hyperinflammatory condition has
also been termed as pediatric multisystem inflammatory
syndrome (PIMS), pediatric inflammatory multisystem
syndrome temporally associated with SARS-CoV-2 (PIM-
TS), pediatric hyperinflammatory syndrome, or pediatric
hyperinflammatory shock (1–3). Initially published case series
from France (4), New-York (5), and England (6) included 35,
33, and 58 children, respectively, whereas further cases are being
published (7, 8). Clinical description revealed from 13 of the
30 British children aged between 4 and 14 years referred to
either warm vasoplegic shock or acute abdominal and sepsis-like
presentations (2). Italian data published on May 2020 described
incomplete Kawasaki Disease-like presentations in 5 of their
10 children aged between 3-16 years of age, six of these ten
patients presented with coronary inflammation and aneurysms
(7). Common observations delineated from this MIS-C referred
to overlapping clinical features of Kawasaki Disease (KD), Toxic
Shock Syndrome, and Macrophage Activation Syndrome with
acute abdominal presentations upon admission (1, 2, 9–13).
While intravenous immunoglobulin (IVIG) is recommended
as first line therapy and is successfully used in KD, some
refractory cases may benefit from treatment with an interleukin-
1 receptor antagonist (Anakinra). Recent evidence suggests
IVIG resistance in some cases of SARS-CoV-2 related MIS-C,
thereby questioning the benefit of immunomodulators such
as IL-1 or IL-6 blocking agents (7, 14). Switzerland reported
over 31,000 persons detected positive to SARS-CoV-2, 3.2%
were children (0-18 years old) (15). From these, 9 children
had MIS-C and documented SARS-CoV-2 infection by PCR or
serologies. We describe the clinical characteristics, laboratory
data and treatment management of the collected 6 of these 9
Swiss children with MIS-C, the remaining 3 have already been
reported in another paper (16).
METHODOLOGY
Our clinical study is a case series that includes all eligible patients
identified during the study registration period (consecutive,
formal). It describes the experience on a small group of
patients (observational, descriptive research design), contains
demographic information about them and was conducted
retrospectively. The patients were treated in the order in which
they were identified, without a group control.
Inclusion Criteria
All patients with a positive serology for SARS-CoV2 (IgG
serology) and symptoms, signs, and laboratory markers in favor
of a systemic hyperinflammatory condition. The patients were
identified by their severe clinical presentation with need of
hospitalization, the increased laboratory inflammatory markers
and their positivity for SARS-CoV2.
Exclusion Criteria
Patients with evidence of a hyperinflammatory state having
negative serology for SARS-CoV2 and negative nasopharyngeal
smear. Patients whose clinical presentation had already been
published in another study, by the hospital center that followed
them. One patient whose parents did not sign the consent about
the publication.
Centers Participated
Four hospitals of Switzerland participated in this study, including
the University Hospital of Lausanne (CHUV), of Geneva (HUG),
of Zurich (USZ) and the Regional Hospital of Bellinzona.
Ethics/Consent
The parents of all patients included in our study were informed
about the management of these hyperinflammatory conditions,
including the different treatments. They signed a consent form
for the participation of their children in the publication and about
their medium and long-term follow-up.
Quantifications of Cytokine Profile
The quantification of cytokines was made by a commercially
available multiplex beads immunoassay, based on the Luminex
platform (Magnetic Luminex R© Performance Assay, R&D
Systems, Minneapolis, USA) according to supplier’s instructions.
Briefly, beads conjugated to the analyte-specific capture
antibodies, samples, standards and controls, were incubated
at room temperature for 3 h. Biotinylated detector antibodies
and R-phycoerythrin–conjugated streptavidin (SAPE) were
subsequently added. The mean fluorescence intensity of each
analyte was read on the Bio-Plex 200 array reader (Bio-Rad
Laboratories) using the Luminex xMAP Technology (Luminex
Corporation). Sample concentrations were calculated using a
five-parameter logistic regression curve (Bio-Plex Manager 6.0).
Interassay variation coefficients were monitored using internal
controls. These were below 15% for all (17).
CLINICAL CHARACTERISTICS,
LABORATORY AND IMAGING FINDINGS
Table 1 displays clinical characteristics, laboratory and imaging
findings as well as treatments of all patients. Five of the 6
patients weremales, with amedian age of 10.5 years (Interquartile
Range (IQR): 8.5-11 years). None presented any co-morbidity.
Four patients were Caucasian, 1 African, and 1 Afro-Caucasian.
None of the patients presented respiratory symptoms or fever
suggestive of COVID-19 in the weeks (4–6 weeks) preceding
their admission. However, family members from patient 1 and
2 presented respiratory symptoms consistent with COVID-19,
a month prior to hospital admission, some family members of
patient 4 had anosmia and mild respiratory symptoms three
weeks prior to admission. SARS-CoV-2 was documented by real
time (RT-PCR) collected from nasopharyngeal swabs (NPS) in 5
of the 6 patients. The PCR threshold cycle (TC) were >35 for
E and N2 genes in patients 1 to 3, thereby supporting a low
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TABLE 1 | Clinical and biological characteristics of Swiss children admitted in Hospital with MIS-C.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Clinical features
Age in years/sex 5/M 8/M 10/M 14/M 11/F 11/M
Ethnicity Caucasian African and
Caucasian
African Caucasian Caucasian Caucasian













Fever>4 days, >40◦C + + + + + +
Abdominal pain - + + + + -
Diarrhea/Emesis +/- +/+ +/+ +/+ -/- +/+
Rash - + - + + +
Conjunctival injection + - - + + +
Lymphadenopathy + - - - - -
Extremity edema/erythema +/+ -/+ -/- -/+ +/+ -/-
Headache/irritability +/+ -/- -/- +/+ -/- +/+
Phono
photophobia/petechiae
+/+ -/- -/- +/+ -/- -/-
Cheilitis - - - - + -
Respiratory insufficiency + + + + + +
Shock - + + + + +
Acute encephalopathy - + - - - +
Cardiopulmonary support











Maximal values in laboratory
C-reactive protein (mg/L)
(Ref: <10 mg/L)
>500 378 176 415 200 200
Procalcitonin (mcg/l) (Ref:
<2 mcg/l)
1.67 6.4 30.2 4.16 10 50
Ferritin (mcg/L) (Ref: 14-101
mcg/L)
176 912 799 1,316 270 1,155
Neutrophil count (G/L) (Ref:
1.5–8.0 G/L)






(ng/L) (Ref: <145 ng/l)
11,383 42,225 10,894 7,206 2,808 >70,000
Interleukin 1 antagonist
receptor (pg/ml) (Ref: ≤720
pg/ml)
2,215 14,273 16,680 Not tested >5,000 >5,000
Interleukin 6 (pg/ml) (Ref:
≤11 pg/ml)
<11 <11 <11 396 90 516
Acute kidney insufficiency - - - - + -
Hepatic cytolysis - - + - + +
SARS-CoV-2 testing
SARS-CoV-2 serology + + + + + +
Imaging
Coronary dilation (Z-score) + (+4.25) +(+2.9) - - - -
IVA aneurysm + - - - - -
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TABLE 1 | Continued
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Cardiopulmonary imaging
(US; X-ray; C/T scan)













































Initiation of treatment (Day 0
= admission to the hospital)
Number of doses of IVIG (2
g/kg)
1 2 0 1 1 1
Day 3 Day 2 + day 3 Day 2 Day 1 Day 1
Acetylsalicylic acid + + - + + +
Methylprednisolone or
prednisone 2 mg/kg/d
- - - + + +
Day 3 (4 weeks in
total)
Day 2 (9 days in
total)
Day 1 (3 days in
total)
Anakinra - 2 mg/kg for 3
days, 4 mg/kg for
>7 days—Started
on day 6
2 mg/kg >7 days
–Started on day 3
2 mg/kg for 10
days —Started on
day 5
1.7 mg/kg for 5
days —Started on
day 4
1.3 mg/kg 2 doses
—Started on day 2






HCQ - - - - - 5 mg/kg 1
dose—Started on
day 3
O2, oxygen; Dobut, dobutamine; ENMG, electroneuromyography; BMI, body mass index; MV, mechanical ventilation; NorAdre, noradrenaline; Mil, Milrinone; Vasopr, vasopressine;
Dopa, dopamine; Adre, adrenaline; Vanco, vancomycin; Amox/clav, amoxicillin/acid clavulanic; Cftx, ceftriaxone; Clinda, clindamycin; Fclox, flucloxacillin; Mero, meropenem; Met,
metronidazole; LVEF, left ventricle ejection function; IVIG, intravenous immunoglobulins; HCQ, hydroxychloroquine; MRI, magnetic resonance imaging; EEG, electroencephalography;
US, ultrasonography; C/T scanner, computed tomography.
IMCU, Intermediate care unit; ICU, Intensive care unit; NPS, nasopharyngeal swab. *Percentile source: WHO Growth Charts.
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viral load. All patients presented a positive IgG serology (Roche
serology) (18).
All 6 patients presented with persistent fever above 39◦C
(more than 5 days) and were treated with broad spectrum
intravenous antibiotics at admission, despite negative blood
cultures. None presented with respiratory symptoms or infiltrates
on chest X-rays suggestive of a lower-respiratory tract SARS-
CoV-2 infection. All presented an important inflammatory
syndrome with high levels of CRP (median: 289 mg/l, IQR:
200-406 mg/l), neutrophilia and increased blood levels IL-
1 receptor antagonist (IL-1RA), except for patient 4, where
IL-1RA serum levels were not measured. Patients 2, 3 and
6 presented a transitory myocardial dysfunction and patients
1 and 2 with a coronary artery dilatation at the admission.
None of the patients had a persistent cardiac dysfunction
upon discharge from the hospital. In addition to fever, patients
1 and 4 initially presented with meningitis-like symptoms;
albeit with normal cerebrospinal fluid findings. Both children
subsequently presented clinical signs, suggestive of Kawasaki
Disease (KD), including persistent fever lasting over 5 days,
bilateral adenopathy, palmar erythema, hand edema and
bilateral conjunctival injection. In addition, patient 1 presented
with a coronary dilation [z-score +4.25 (19)] with IVA
aneurysm (aneurysm of the left interventricular coronary) on
cardiac echography. Patients 2, 3, 5, and 6 presented an
acute abdominal clinical picture, with hemodynamic instability
requiring aminergic support. Patients 2 and 3 presented with an
acute-appendicitis-like clinical picture. Patients 5 and 6 presented
some acute abdominal symptoms associated with conjunctival
injection and a rash, albeit not meeting all criteria for complete
KD. Serum cytokine profile investigations showed increased
IL1RA levels (8 to 22-fold) in 5 of the 6 patients (one patient had
not been tested), whereas IL-6 serum levels were increased only
in the 3 patients of the 6 who were tested. The rest of the cytokine
profile was normal.
The treatments introduced for each patient and their CRP
values are shown in Figure 1. With exception of patient
3, all patients received at least one dose of intravenous
immunoglobulins (IVIG 2 g/kg). Patient 1 benefited of one dose
of IVIG with a positive clinical and biological response. Patient
2 received a second dose of IVIG (the same dose as the first
one administrated, 2 g/kg) 48 h apart (on day 3 of admission)
and subcutaneous anakinra at 2 mg/kg/day for 3 days (started
on day 6), increased up to 4 mg/kg/day given his persistent
fever and increased inflammatory parameters. Patient 3 only
received anakinra (2 mg/kg) with favorable clinical and biological
response. Patients 4, 5, and 6 required one dose of IVIG followed
by anakinra (2 mg/kg) and steroids for patient 4, which resulted
in the resolution of inflammatory parameters. Patient 4 was
initially under methylprednisolone (for one week) and then he
benefited from a relay by prednisone with a tapering regimen
over 3 weeks. In addition, patients 5 and 6 also received one
dose of tocilizumab (8 mg/kg). Patient 5 received tocilizumab
in addition to steroids which were started the day before,
because of persisting fever and hemodynamic instability, with a
good initial response. However, after 24 h, the patient presented
again fever, diffuse myalgia, burning on palms of hand and
feet and hemodynamic instability, in tandem with persistence
of inflammatory markers. All these reasons have motivated the
addition of Anakinra. Patient 6 was remaining sub febrile with a
massive inflammatory syndrome, pejoration of the Pro-BNP, and
cardiac echography showing an alteration of the cardiac function
with suspicion of myocarditis, despite 2 doses of Anakinra and
those parameters havemotivated the addition of Tocilizumab one
day after the introduction of Anakinra and hydroxychloroquine.
It is important to highlight that the results of the cytokines
were not available when we considered to change treatments.
Four patients (patient 1, 4, 5, and 6) were also treated with
acetylsalicylic acid at anti-inflammatory doses.
DISCUSSION
We report on a cohort of Swiss children with SARS-CoV2
related MIS-C presenting with clinical features compatible with
Incomplete KD and Toxic Shock Syndrome associated to a
cytokine storm suggestive of a macrophage activation syndrome
(MAS) without fulfilling the criteria for Hemophagocytic
Lymphohistiocytosis (HLH). As already documented elsewhere
(2, 4, 6, 7, 16, 20) and as described in 4 of our 6 patients,
many children with MIS-C present some criteria for complete
or incomplete KD, appendicitis-like abdominal symptoms
and important hyperinflammatory syndrome. Important
epidemiological differences between KD and MIS-C include
the ethnicity and age of affected patients. While KD primarily
affects infants and young children with a 20-fold increased
incidence in Asian children (21, 22), MIS-C has been reported
among older children, predominantly from an African and
Hispanic ethnic background, but this is not always the case
(21, 22). These findings could suggest an underlying specific
host polymorphism triggering a cytokine cascade secondary to
SARS-CoV-2 infection. Hospitalizations due to SARS-CoV-2
were higher in the same geographic areas in which we later
discovered the cases of MIS-C, thereby reinforcing an association
between MIS-C and SARS-CoV-2. The contribution of a specific
SARS-CoV-2 strain is debated, as some of the European SARS-
CoV-2 strains could harbor a mutation favoring TCR binding
(23) thereby possibly explaining the occurrence of MIS-C in
Western countries rather than in Asia. Yet, several different
strains have been documented in Europe and in the US (24). As
such, the pathophysiology of progression to MIS-C in specific
children remains unclear. The contribution of a specific strain
in our cohort of patients could not be documented given that
genotyping analyses were limited due to the very low viral loads
detection. MIS-C also differs from acute COVID-19 illness which
tends to be most severe in infants <1 year of age (7, 25, 26).
In addition, MIS-C is typically documented up to a month
after the peak of SARS-CoV-2, thereby coinciding with the
timing of acquired immunity and suggesting a post-infectious
inflammatory reaction rather than an acute infectious process
(7, 21, 22, 27).
The pathophysiology and the mechanisms by which SARS-
CoV-2 triggers an abnormal immune response leading to
MIS-C remain poorly understood. Current evidence reports
a hyperinflammatory reaction presenting similarities with
TSS, incomplete KD and MAS, suggesting activation of
the innate immune response with massive pro-inflammatory
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FIGURE 1 | continued
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FIGURE 1 | Chronology of the inflammatory markers and the treatments used. IVIG, intravenous immunoglobulins.
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production (28). SARS-CoV-2 may act as a superantigen (23)
similarly to the staphylococcal enterotoxin B (SEB) known
to bind to the costimulatory molecule CD28 and the T cell
receptor (TCR), thus mediating TSS. The activation of the innate
immunity during SARS-CoV-2 infection leads to a cytokine
release syndrome named “cytokine storm” characterized by
persistent fever and markedly elevated cytokines mostly TNF-
α, IL-1β, IL-1RA, sIL-2Rα, IL-6, IL-10, IL-17, IL-18, IFN -γ,
MCP-3, M-CSF, MIP-1a, G-CSF, IP-10, and MCP (29). Most
of recent published case series of MIS-C patients documented
increased IL-6 levels; (28, 30, 31) the serum levels of other pro-
inflammatory cytokines being underreported, except for normal
levels of IL-1ß in one case (28). Our case series differs in
the documentation of very high serum interleukin-1 receptor
antagonist (IL-1RA) levels, an important marker for innate
immunity activation, among 5 patients; IL-6 serum levels being
elevated in only 3 of our 6 patients. These findings may
suggest that the activation of the IL-1 pathway also represents
an important mechanism of activation in MIS-C as already
documented in other conditions such as MAS, TSS, and KD (32).
Given similarities between MIS-C and KD and the contribution
of IVIG in TSS, all but one patient were first started on
IVIG with or without corticosteroids (16, 21, 22). Three of
our patients received either parenteral methylprednisolone or
a short course of oral prednisone. Recent evidence reports on
a one-third reduced deaths among intubated and ventilated
adults with acute COVID-19 treated with dexamethasone for 10
days when compared with patients randomized to usual care
alone (33). As such, the benefit of dexamethasone has mostly
been suggested among adults with severe COVID-19 disease,
although it might also be useful in MIS-C given its inhibition
of cytokine production (33) In addition, glucocorticoids are also
recommended for patients with KD with persistent fever after
IVIG or coronary arteries dilatation and are considered among
those with cytokine release syndrome. In this regard, the benefits
of glucocorticoids as first-line treatment for inflammatory
diseases remain undisputable, although biological agents are also
attractive alternatives as reported from children with JIA (34).
Several reports refer to the use of anakinra (an IL-1 receptor
antagonist RA recombinant) and tocilizumab (an antibody
against the IL-6 receptor) in patients infected by SARS-CoV-2
with hyperinflammatory state and in a minority of those with
MIS-C in addition to IVIG and glucocorticoids (5, 20, 30, 35).
Anakinra is specifically attractive due to its good safety profile
and short half-life.
This case series displays a range of heterogeneous treatments,
prescribed by different hospitals in Switzerland, which allows us
to draw a first set of meaningful conclusions on the effectiveness
of combinations of different drugs on patients infected by SARS-
CoV-2. Specifically, only one patient (patient 1) received solely
IVIG, and the remaining five received anakinra either alone
or in combination with other drugs. From these five patients,
one (patient 3) only received anakinra and the four others also
received additional immunomodulators. Notably, one patient
(patient 2) received solely IVIG as supplement treatment and the
remaining three (patients 4,5 and 6) received steroids in addition
to IVIG; two out of them (patients 5 and 6) also received one
course of tocilizumab. All patients had a favorable response to
these different treatments.
In conclusion two of our six patients were successfully
treated with anakinra without receiving steroids or other
immunosuppressive treatment. This observation combined
with the documentation of increased IL-1RA levels in 5
of our 6 patients further supports the use of anakinra
in children presenting a multi-system inflammatory
syndrome (MIS-C). Concerning the other targeted
treatments and notably the tocilizumab, it could be either
an alternative or a supplementary treatment depending on
the cytokine profile presented by the patient, which varies
between individuals.
Despite the limited number of cases included in our study
in addition to previous reports on 3 of the 9 Swiss MIS-C, we
believe that we add on current published evidence by providing
a complete cytokine profile from most of the included cases and
provide some evidence on the use of anakinra inMIS-C. This type
of study is most useful for describing the potential effectiveness
of new interventions and for describing the effectiveness of
interventions on unusual diagnoses.
In conclusion, our case series reports on clinical and
laboratory findings of most of Swiss cases with MIS-C and
suggests the use of anakinra as effective treatment, especially in
children with documented high IL-1RA levels.
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